T2DM patients received initial triple therapy with metformin/pioglitazone/exenatide (n = 29) vs. metformin, followed by stepwise addition of glipizide and then insulin glargine (n = 26), achieving glycemic control (HbA1c < 6.5%). The gene discussed is INS; the disease is type 2 diabetes mellitus.